Horizon Pharma plc. Expands U.S. Headquarters With Opening Of Chicago Office

DUBLIN, IRELAND--(Marketwired - February 17, 2015) - Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced it has opened a Chicago office.

The office, which is located at 150 South Wacker Drive, will primarily house commercial, corporate analytics and business development staff.

"More than twenty-five percent of our Illinois employees live in the City of Chicago and we felt it was important to establish a city presence in order to assist our employees in maximizing their personal and professional potential," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma, plc. "As one of the fastest growing biopharmaceutical companies in Illinois, a city presence offers access to top talent and easier access to the growing biotech and biopharma community."

"I am pleased that Horizon Pharma recognizes the thriving healthcare economy in Chicago and is making this investment in the city," said Mayor Rahm Emanuel. "Chicago's diverse and deep pool of talent remains a significant driver in companies like this making the decision to locate here."

About Horizon Pharma plc
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com.